Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

STTK vs PYPD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–3 Matrix Metrics)

STTK Overall Winner 6-Pillar Tally: STTK 2 – 2 PYPD (2 Tie) Matrix Metrics: STTK 3 – 3 PYPD

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). STTK carries a Unified Composite Score of 52.1/100 (HOLD) at $4.52 (N/M Forward P/E, 0.0% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. PYPD 31.1/100 SELL) and 1.45β · 76% Vol risk profile, whereas PYPD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.6); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STTK vs PYPD
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.52
-3.0% 1D
Market Cap $473.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.45β · 76% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 36
RSI-14: 35.6 · SMA20: $5.18 · SMA50: $5.71
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40

6-Pillar Scorecard Institutional Category Breakdown (STTK 2 – 2 PYPD)

Columns: Metric · STTK · PYPD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PYPD
Revenue Growth (YoY) -66.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $473.6M $132.2M
3. Profitability & Quality STTK
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -47.2% -243.6%
4. Balance Sheet & Cash Flow STTK
Cash Generation (TTM) -$50M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $59M Net Cash $5.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 72.4% (10th %ile) 106.3% (12th %ile)
Put/Call OI Skew 4.54x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STTK (3) vs PYPD (3)
Institutional Metric STTK PYPD Criterion Row Edge
Market Capitalization
Scale
$473.6M $132.2M Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-66.6% +0.0% Higher Growth PYPD
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-47.2% -243.6% Higher ROE STTK
52-Week Range Position
Momentum
42% ($2–$8) 80% ($4–$7) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
1.45β · 76% Vol 0.89β · 59% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 31.1 / 100 (SELL) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M ($59M Net Cash) N/A ($5.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +47.69 pp
STTK: -15.83% · PYPD: +31.86%
3M Horizon PYPD +69.43 pp
STTK: -40.99% · PYPD: +28.44%
6M Horizon PYPD +57.12 pp
STTK: -21.93% · PYPD: +35.19%
1Y Horizon STTK +61.18 pp
STTK: +140.43% · PYPD: +79.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STTK vs PYPD. Trailing 12-month operating profitability (STTK 0.0% vs PYPD 0.0%) and valuation multiples (STTK N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STTK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-47.2% · N/M
PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STTK BREAKDOWN
59d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.54x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $473.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STTK vs PYPD Key Questions & Quantitative Answers

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). STTK carries a Unified Composite Score of 52.1/100 (HOLD) at $4.52 (N/M Forward P/E, 0.0% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. PYPD 31.1/100 SELL) and 1.45β · 76% Vol risk profile, whereas PYPD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.6); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PYPD leads the Growth & Scale pillar: STTK posts -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, STTK generates N/A in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, STTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.

STTK and PYPD trade at balanced relative valuation multiples. STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STTK (-47.2% ROE) versus PYPD (-243.6% ROE) capital efficiency.

In options market volatility and institutional positioning, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.45β · 76% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.